Form 4: Nurix Therapeutics Executive Gwenn Hansen Reports Stock Option and Restricted Stock Unit Grants

Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, reports the acquisition of stock options and restricted stock units.

Summary

• Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of 75,000 employee stock options with an exercise price of $17.12, vesting monthly from March 11, 2025, to February 10, 2028.
• Hansen also acquired 34,300 restricted stock units (RSUs) that vest quarterly over three years, starting July 30, 2025.
• Each RSU represents a contingent right to receive one share of Nurix Therapeutics common stock.
• The reported transactions were signed off by Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen, on February 13, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grants are standard practice and incentivize the executive, but don't represent a major shift in the company's outlook.

Positives

• The grant of stock options and RSUs to the Chief Scientific Officer aligns her interests with those of the shareholders.
• Vesting schedules tied to continued service incentivize long-term commitment.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest an expectation of continued service from the executive.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry typically include a mix of salary, stock options, and restricted stock units.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar compensation structures to incentivize their executives.
• The vesting schedules and exercise prices are generally benchmarked against industry standards to ensure competitiveness and alignment with performance goals.

Stakeholder Impact

• Shareholders may view the grants positively as they align executive interests with company performance.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates